ORBIMED ADVISORS LLC → Adaptimmune Therapeutics PLC

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

31 filings by this filer

30 other filings in the data moat

Short Interest

—

Not in latest FINRA snapshot

Other Filings by ORBIMED ADVISORS LLC

Filed	Form	Issuer	Stake	Shares
2026-04-10	SCHEDULE 13D/A	Adicet Bio, Inc. ACET	8.80%	844,787	view →
2018-07-02	SC	Aerpio Pharmaceuticals, Inc. WHWK	—	—	view →
2018-05-02	SC	PIERIS PHARMACEUTICALS, INC. PVLA	—	—	view →
2018-04-12	SC	SYNLOGIC, INC. SYBX	—	—	view →
2018-03-14	SC	Corvus Pharmaceuticals, Inc. CRVS	—	—	view →
2018-03-06	SC	ViewRay, Inc.	—	—	view →
2018-02-16	SC	Intellia Therapeutics, Inc. NTLA	—	—	view →
2018-02-15	SC	Xtant Medical Holdings, Inc. XTNT	—	—	view →
2018-02-07	SC	RHYTHM PHARMACEUTICALS, INC. RYTM	—	—	view →
2018-01-29	SC	Ascendis Pharma A/S ASND	—	—	view →
2018-01-29	SC	Intellia Therapeutics, Inc. NTLA	—	—	view →
2018-01-26	SC	Arsanis, Inc. XFOR	—	—	view →
2018-01-26	SC	SteadyMed Ltd.	—	—	view →
2018-01-26	SC	scPharmaceuticals Inc.	—	—	view →
2018-01-26	SC	ALPINE IMMUNE SCIENCES, INC.	—	—	view →
2018-01-26	SC	PIERIS PHARMACEUTICALS, INC. PVLA	—	—	view →
2018-01-26	SC	Verona Pharma plc	—	—	view →
2018-01-26	SC	Sorrento Tech, Inc.	—	—	view →
2018-01-26	SC	ALPINE IMMUNE SCIENCES, INC.	—	—	view →
2018-01-26	SC	ViewRay, Inc.	—	—	view →

Showing 20 of 30

ORBIMED ADVISORS LLC → Adaptimmune Therapeutics PLC

Item 4 — Purpose of Transaction

Cross-References

Other Filings by ORBIMED ADVISORS LLC

Want this depth on every filing the moment it hits SEC EDGAR?